Harm reduction programs for addiction treatment Review article
Article Sidebar
Main Article Content
Abstract
The limited effectiveness of anti-addiction pharmacotherapy encourages the introduction of so-called harm reduction programs. They allow you to significantly reduce the health, social and economic damages of addicts and their families. The simplest form of harm reduction is the substitution therapy. You can use the same psychoactive substance (e.g. nicotine in patches) or give a different one (e.g. methadone vs morphine). Harm reduction programs are typically criticized for allegedly extending the addiction period. However, the experience of many countries shows that they are effectively contributing to recovery from addiction. Considering the fact that smoking is the main modifiable cause of diseases, and at the same time that there are no sufficiently effective methods of treating this addiction, the use of harm reduction programs – based on the so-called novel tobacco products – seems to be the most appropriate choice. Precedent registrations of subsequent Modified Risk Tobacco Products in the US create conditions to pragmatically replace tobacco products in which smoking occurs – other, smokeless, and at the same time less harmful.
Article Details
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Beirness DJ, Notarandrea R, Jesseman R et al. Reducing the Harm of “Harm Reduction”. Clinical Pharmacology & Therapeutics. 2008; 83(4): 523-5.
3. Dworniczak M. Redukcja szkód spowodowanych paleniem tytoniu – czas na działania oddolne. Med Rodz. 2018; 21(3): 292-301.
4. Łoza B, Jahnz-Różyk K, Karkowska D et al. Możliwości realizacji programu redukcji szkód u osób palących tytoń. Stan aktualny i rekomendacje. Neuropsychiatria. 2019; 11(3-4): 41-50.
5. GFN: stosowanie nowatorskich wyrobów tytoniowych znacząco obniża śmiertelność wśród palaczy. ISB Zdrowie. 2019.
6. Sutanto E, Miller C, Smith DM et al. Prevalence, Use Behaviors, and Preferences among Users of Heated Tobacco Products: Findings from the 2018 ITC Japan Survey. Int J Environ Res Public Health. 2019; 16: 4630.
7. Kazubski BM, Durlik J, Balwicki Ł et al. Program zwalczania następstw zdrowotnych używania wyrobów tytoniowych i wyrobów powiązanych w ramach Narodowego Programu Zdrowia. Ankietowe badanie młodzieży. Wrocław 2019.
8. E-papierosy zmniejszają liczbę palaczy na świecie. ISB Zdrowie. 2018.
9. McNeill A, Brose LS, Calder R et al. Evidence review of e-cigarettes and heated tobacco products 2018. A report coomissioned by Public Health England. Public Health England, Londyn 2018.
10. Prokopowicz A. Redukcja szkód związana z przyjmowaniem substancji psychoaktywnych. Med Rodz. 2018; 21(1): 73-9.
11. FDA. FDA permits sale of IQOS Tobacco Heating System through premarket tobacco product application pathway.
12. Peruga A, Fayokun R, Mauer-Stender K et al. Heated tobacco products. A brief. WHO, Kopenhaga 2020.
13. Peruga A, Fayokun R, Mauer-Stender K et al. Electronic nicotine and non-nicotine delivery systems. A brief. WHO, Kopenhaga 2020.
14. Lothane Z. W obronie Paula Schrebera. Neuropsychiatria. Przegląd Kliniczny. 2009; 1(3): 5-14.